Pharmacogenomics in Pediatric Populations

Pharmacogenomics in pediatric populations concerns how inherited variation in drug-metabolizing enzymes, transporters, and drug targets expresses itself against the moving background of childhood development. From the neonate to the adolescent, the activity of enzymes such as the cytochrome P450 family and conjugating enzymes follows maturational trajectories, so the drug-response phenotype produced by a given genotype is not fixed but changes as the child grows. The field studies this interaction between genotype and ontogeny.

Definition

Pharmacogenomics in pediatric populations is the study of how heritable determinants of drug response interact with developmental changes in the expression and activity of drug-metabolizing enzymes, transporters, and targets across infancy, childhood, and adolescence to shape drug exposure and effect.

Scope

The entry covers the developmental (ontogenic) regulation of drug-handling pathways, the resulting discordance between genotype and observed phenotype at different ages, and the major pediatric gene-drug relationships addressed by implementation guidelines, including thiopurines in childhood leukemia. It treats pediatric pharmacogenomics as a methodological and conceptual topic, not as clinical or dosing guidance.

Core questions

• How does the maturation of drug-metabolizing enzymes modify the phenotype predicted by a child's genotype?
• At what developmental stages does genotype become the dominant determinant of drug response?
• Which pediatric gene-drug pairs have sufficient evidence to guide interpretation, and which are extrapolated from adults?
• How does ontogeny complicate the genotype-to-phenotype translation that is more stable in adults?

Key concepts

• Developmental pharmacology
• Ontogeny of cytochrome P450 enzymes
• Genotype-phenotype discordance in early life
• Maturational pharmacokinetics
• TPMT and NUDT15 in thiopurine response
• Extrapolation from adult evidence

Mechanisms

Drug disposition in children is shaped by age-dependent changes in body composition, organ function, and especially the expression of drug-metabolizing enzymes and transporters. Many cytochrome P450 enzymes and phase II enzymes are low or absent at birth and rise toward, or transiently exceed, adult activity over months to years; some pathways follow distinct switches in expression during infancy. A pharmacogenomic variant is therefore read against this developmental baseline: a reduced-function allele may matter little when the relevant enzyme is not yet expressed and more once it matures. Where an enzyme's activity is largely genetically determined and developmentally stable, such as thiopurine S-methyltransferase, genotype-guided interpretation is more directly transferable from adults to children, which is why thiopurine pharmacogenetics is a well-developed pediatric example.

Clinical relevance

This topic helps clinicians and trainees understand why pediatric pharmacogenomic results are interpreted together with the child's developmental stage and why adult gene-drug evidence cannot always be applied unchanged to children. It is reference-educational: it explains how pediatric drug-response evidence is generated and reasoned about and is not a basis for individual dosing or treatment decisions.

Epidemiology

Pharmacogene allele frequencies in children mirror those of their source populations, but the clinical manifestation of a variant depends on developmental stage; pediatric pharmacogenomic evidence is concentrated in a few therapeutic areas, with childhood acute lymphoblastic leukemia and thiopurine therapy among the most studied.

Evidence & guidelines

Implementation guidance for some gene-drug pairs is informed by pediatric data, most notably thiopurine dosing in relation to TPMT and NUDT15 genotype, while for many other drugs pediatric recommendations are extrapolated from adult studies because dedicated pediatric pharmacogenomic trials are limited. PharmGKB and implementation consortia curate the underlying evidence.

History

Pediatric drug therapy was long described in terms of body-weight scaling of adult doses, but developmental pharmacology established that maturation of drug-handling pathways is non-linear and pathway-specific. As germline pharmacogenomic variation was characterised, the field recognised that genotype and ontogeny jointly determine response in children, and thiopurine pharmacogenetics in childhood leukemia became an early translational success.

Debates

Can adult pharmacogenomic recommendations be extrapolated to children?

Because enzyme expression matures with age, a variant's effect on drug response can differ between adults and young children, so the extent to which adult gene-drug guidance applies across pediatric age ranges remains uncertain and dependent on the developmental stability of the pathway involved.

Key figures

• Gregory Kearns
• J. Steven Leeder
• Mary Relling
• William Evans

Seminal works

• kearns-2003
• evans-2003
• relling-2015

Frequently asked questions

Why can a child's drug-response genotype predict a different phenotype than the same genotype in an adult?

Because many drug-metabolizing enzymes mature gradually after birth, the functional consequence of a variant depends on how much of the relevant enzyme is expressed at the child's developmental stage.

Which is the most established pediatric pharmacogenomic example?

Thiopurine therapy in childhood leukemia, where TPMT and NUDT15 genotype relate to the risk of toxicity, is among the most developed pediatric gene-drug relationships in implementation guidance.